Chronic obstructive pulmonary disease and cerebrovascular diseases: functional and clinical aspect of comorbidity


Cite item

Full Text

Abstract

Literature data of chronic obstructive pulmonary disease (COPD) and cerebrovascular diseases (CVD) comorbidity are represented in this review. Key aspects of this interaction and its importance for clinical medicine have been considered. CVD and COPD are the main mortality factors in adults, which contribute to great economic wastes. The incidence of chronic cerebral ischemia for COPD patients is almost three times as high as for general population. The incidence of ischemic stroke for COPD patients is 1,2 times higher than in general population. For hemorrhagic stroke and subarachnoid haemorrhages, this figures are 1,3 and 1,46 respectively. Chronic systemic inflammation, tissue hypoxia and oxidative stress play the crucial role in respiratory and cerebrovascular comorbidity. Metabolites of these processes (especially proinflammatory cytokines, reactive oxygen species, C-reactive protein and some neurotrophins) increase the permeability of blood-brain barrier, destroy brain cells and activate atherogenesis in pre - and intracerebral arteries. Endothelial dysfunction affects autoregulation of cerebral circulation. Systemic symptoms of COPD are closely associated with different structural-functional disorders of the brain such as reduction in white matter integrity, grey matter volume reduction and cerebral microbleeds. Also, venous encephalopathy is developed as a result of intrathoracic pressure elevation and stasis in superior vena cava system. These processes result in neurological symptomatology. The intensity of symptoms depends on COPD severity. The occurrence of cognitive impairment, psychic tension, depression, panic disorders also increases. However COPD and CVD comorbidity is an important problem of modern medicine, pathophysiologic mechanisms and clinic aspects of this problem remain unresolved. Understanding of their role opens perspectives for rational pharmacotherapy.

About the authors

B I Geltser

Pacific state medical university; Far Eastern federal university

д.м.н., проф., член-корр. РАН, советник ректора по науке и инновациям Тихоокеанского государственного медицинского университета; директор департамента фундаментальной и клинической медицины школы биомедицины Дальневосточного федерального университета Vladivostok, Russia

I G Kurpatov

Pacific state medical university

аспирант института нормальной и патологической физиологии Vladivostok, Russia

V N Kotelnikov

Pacific state medical university

Email: vkotelnikov@hotmail.com
д.м.н., проф. учебного военного центра Vladivostok, Russia

Yu V Zayats

Far Eastern federal university

аспирант школы биомедицины Vladivostok, Russia

References

  1. Ehteshami-Afshar S, Fitz-Gerald J.M, Doyle-Waters M.M, Sadatsafavi M. The global economic burden of asthma and chronic obstructive pulmonary disease. The International Journal of Tuberculosis and Lung Disease. International Union Against Tuberculosis and Lung Disease. 2016; 20(1): 11-23. doi: http: //dx. doi. org/10. 5588/ijtld. 15. 0472.
  2. Shibata Y. Epidemiology of COPD: Why Is the Disease So Poorly Recognized? Chronic Obstructive Pulmonary Disease. Springer Nature. 2016: 17-28. doi: http: //dx. doi. org/10. 1007/978-981-10-0839-9_2.
  3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available at: http: //www. goldcopd. org (accessed 30 Jul 2016).
  4. Srivastava K, Thakur D, Sharma S, Punekar Y.S. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease. Pharmacoeconomics. 2015; 33: 467-488. doi: http: //dx. doi. org/10. 1007/s40273-015-0252-4.
  5. Tang Z, Zhou T, Luo Y, Xie C, Huo D, Tao L et al. Risk Factors for Cerebrovascular Disease Mortality among the Elderly in Beijing: A Competing Risk Analysis. Stover C.M, editor. PLoS ONE. Public Library of Science (PLoS). 2014; 9(2): e87884. doi: http: //dx. doi. org/10. 1371/journal. pone. 0087884.
  6. Tzanakis N, Hillas G, Perlikos F, Tsiligianni I. Managing comorbidities in COPD. International Journal of Chronic Obstructive Pulmonary Disease. Dove Medical Press Ltd. 2015; 10(1): 95-109. doi: http: //dx. doi. org/10. 2147/copd. s54473.
  7. Müllerova H, Agusti A, Erqou S, Mapel D.W. Cardiovascular Comorbidity in COPD. Chest Elsevier BV. 2013; 144(4): 1163-1178. doi: http: //dx. doi. org/10. 1378/chest. 12-2847.
  8. Smith M, Wrobel J. Epidemiology and clinical impact of major comorbidities in patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease. Dove Medical Press Ltd. 2014; 9: 871-888. doi: http: //dx. doi. org/10. 2147/copd. s49621
  9. Bernardo I, Bozinovski S, Vlahos R. Targeting oxidant - dependent mechanisms for the treatment of COPD and its comorbidities. Pharmacology & Therapeutics Elsevier BV. 2015; 155: 60-79. doi: http: //dx. doi. org/10. 1016/j. pharmthera. 2015. 08. 005.
  10. Kaźmierczak M, Ciebiada M, Pękala-Wojciechowska A, Pawłowski M, Nielepkowicz-Goździńska A, Antczak A. Evaluation of Markers of Inflammation and Oxidative Stress in COPD Patients with or without Cardiovascular Comorbidities. Heart, Lung and Circulation Elsevier BV. 2015; 24(8): 817-823. doi: http: //dx. doi. org/10. 1016/j. hlc. 2015. 01. 019.
  11. Terzikhan N, Verhamme K.M.C, Hofman A, Stricker B.H, Brusselle G.G, Lahousse L. Prevalence and incidence of COPD in smokers and non - smokers: the Rotterdam Study. European Journal of Epidemiology Springer Nature. 2016; 31(8): 785-792. doi: http: //dx. doi. org/10. 1007/s10654-016-0132-z.
  12. Lahousse L, Tiemeier H, Ikram M.A, Brusselle G.G. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respiratory Medicine Elsevier BV. 2015; 109(11): 1371-1380. doi: http: //dx. doi. org/10. 1016/j. rmed. 2015. 07. 014.
  13. Söderholm M, Inghammar M, Hedblad B, Egesten A, Engström G. Incidence of stroke and stroke subtypes in chronic obstructive pulmonary disease. European Journal of Epidemiology Springer Nature. 2015; 31(2): 159-168. doi: http: //dx. doi. org/10. 1007/s10654-015-0113-7.
  14. Yildiz S, Kaya I, Cece H, Gencer M, Ziylan Z, Yalcin F et al. Impact of COPD exacerbation on cerebral blood flow. Clinical Imaging Elsevier BV. 2012; 36(3): 185-190. doi: http: //dx. doi. org/10. 1016/j. clinimag. 2011. 08. 021
  15. Ives S.J, Harris R.A, Witman M.A.H, Fjeldstad A.S, Garten R.S, Mc Daniel J et al. Vascular Dysfunction and Chronic Obstructive Pulmonary Disease: The Role of Redox Balance. Hypertension Ovid Technologies (Wolters Kluwer Health). 2013; 63(3): 459-467. doi: http: //dx. doi. org/10. 1161/hypertensionaha. 113. 02255.
  16. Квасникова Ю. В. Клинико - функциональные ипсихологические особенности у больных хронической обструктивной болезнью легких на разных стадиях формирования хронического легочного сердца: Автореф. дис. … канд. мед. наук, Санкт-Петербург; 2013. Доступно по: http: //www. dlib. rsl. ru/loader/view/01005538199?get=pdf
  17. Gudmundsson G, Gislason T, Janson C, Lindberg E, SuppliUlrik C, Brøndum E et al. Depression, anxiety and health status after hospitalisation for COPD: A multicentre study in the Nordic countries. Respiratory Medicine Elsevier BV. 2006; 100(1): 87-93. doi: http: //dx. doi. org/10. 1016/j. rmed. 2005. 04. 003.
  18. Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E et al. Cerebral stroke injury: the role of cytokines and brain inflammation. Journal of Basic and Clinical Physiology and Pharmacology. Walter de Gruyter GmbH. 2014; 25(2): 131-137. doi: http: //dx. doi. org/10. 1515/jbcpp-2013-0121.
  19. Zhang H, Wang X, Lin J, Sun Y, Huang Y, Yang T et al. Grey and white matter abnormalities in chronic obstructive pulmonary disease: a case - control study. BMJ Open BMJ. 2012; 2(2): e000844. doi: http: //dx. doi. org/10. 1136/bmjopen-2012-000844.
  20. Barnes P.J. Chronic Obstructive Pulmonary Disease: Effects beyond the Lungs. PLoS Medicine. Public Library of Science (PLoS). 2010; 7(3): e1000220. doi: http: //dx. doi. org/10. 1371/journal. pmed. 1000220.
  21. Urakova M.A, Bryndina I.G. Surfactant in the Water Balance of the Lungs after Intracerebral Hemorrhage in Conditions of Capsaicin Blockade of the Vagus Nerve. Neuroscience and Behavioral Physiology. Springer Nature. 2016; 46(6): 639-643. doi: http: //dx. doi. org/10. 1007/s11055-016-0290-1.
  22. Tarabay M, Elshazli R, Settin A. African vs. Caucasian and Asian difference for the association of interleukin-10 promotor polymorphisms with type 2 diabetes mellitus (a meta - analysis study). Meta Gene Elsevier BV. 2016; 9: 10-17. doi: http: //dx. doi. org/10. 1016/j. mgene. 2016. 02. 006.
  23. Guleria R, Arora S, Kumar G, Mohan A. Does Systemic Inflammation Effects Nutritional Status and Severity of COPD? Chest Elsevier BV. 2016; 150(4): 850A. doi: http: //dx. doi. org/10. 1016/j. chest. 2016. 08. 950.
  24. Aleksandrova N.P, Danilova G.A, Aleksandrov V.G. Cyclooxygenase pathway in modulation of the ventilatory response to hypercapnia by interleukin-1β in rats. Respiratory Physiology & Neurobiology Elsevier BV. 2015; 209: 85-90. doi: http: //dx. doi. org/10. 1016/j. resp. 2014. 12. 006.
  25. Brough D, Galea J. The role of inflammation and interleukin-1 in acute cerebrovascular disease. Journal of Inflammation Research Dove Medical Press Ltd. 2013; 121: 121-128. doi: http: //dx. doi. org/10. 2147/jir. s35629.
  26. Elkind M.S.V. Impact of innate inflammation in population studies. Annals of the New York Academy of Sciences Wiley-Blackwell. 2010; 1207(1): 97-106. doi: http: //dx. doi. org/10. 1111/j. 1749-6632. 2010. 05736. x.
  27. Shoamanesh A, Preis S.R, Beiser A.S, Vasan R.S, Benjamin E.J, Kase C.S et al. Inflammatory biomarkers, cerebral microbleeds, and small vessel disease: Framingham Heart Study. Neurology Ovid Technologies (Wolters Kluwer Health). 2015; 84(8): 825-832. doi: http: //dx. doi. org/10. 1212/wnl. 0000000000001279.
  28. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nature Reviews Drug Discovery Springer Nature. 2010; 9(6): 482-493. doi: http: //dx. doi. org/10. 1038/nrd3030.
  29. Xie Z-K, Huang Q-P, Huang J, Xie Z-F. Association between the IL1B, IL1RN polymorphisms and COPD risk: A meta - analysis. Scientific Reports Springer Nature. 2014; 4: 6202. doi: http: //dx. doi. org/10. 1038/srep06202.
  30. Horita N, Kaneko T. Assessment of Inflammation in COPD: Are there any Biomarkers that can be used to Assess Pulmonary and Systemic Inflammation? Chronic Obstructive Pulmonary Disease. Springer Nature. 2016; 135-158. doi: http: //dx. doi. org/10. 1007/978-981-10-0839-9_8.
  31. Romero J.R, Preis S.R, Beiser A.S, De Carli C, Lee D.Y, Viswanathan A et al. Lipoprotein Phospholipase A2 and Cerebral Microbleeds in the Framingham Heart Study. Stroke. Ovid Technologies (Wolters Kluwer Health). 2012; 43(11): 3091-3094. doi: http: //dx. doi. org/10. 1161/strokeaha. 112. 656744.
  32. Wright C.B, Moon Y, Paik M.C, Brown T.R, Rabbani L, Yoshita M et al. Inflammatory Biomarkers of Vascular Risk as Correlates of Leukoariosis. Stroke. Ovid Technologies (Wolters Kluwer Health). 2009; 40(11): 3466-3471. doi: http: //dx. doi. org/10. 1161/strokeaha. 109. 559567.
  33. Drummond G.R, Selemidis S, Griendling K.K, Sobey C.G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nature Reviews Drug Discovery. Springer Nature. 2011; 10(6): 453-471. doi: http: //dx. doi. org/10. 1038/nrd3403.
  34. Dayal S, Wilson K.M, Motto D.G, Miller F.J, Chauhan A.K, Lentz S.R. Hydrogen Peroxide Promotes Aging-Related Platelet Hyperactivation and Thrombosis. Circulation Ovid Technologies (Wolters Kluwer Health). 2013; 127(12): 1308-1316. doi: http: //dx. doi. org/10. 1161/circulationaha. 112. 000966.
  35. Rahman I. Pharmacological antioxidant strategies as therapeutic interventions for COPD. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. Elsevier BV. 2012; 1822(5): 714-728. doi: http: //dx. doi. org/10. 1016/j. bbadis. 2011. 11. 004.
  36. Austin V, Crack P.J, Bozinovski S, Miller A.A, Vlahos R. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clinical Science. Portland Press Ltd. 2016; 130(13): 1039-1050. doi: http: //dx. doi. org/10. 1042/cs20160043.
  37. Гельцер Б. И., Бродская Т. А., Котельников В. И., Агафонова И. Г., Лукьянов П. А. Эндотелиальная дисфункция церебральных и магистральных артерий при хронической обструктивной болезни легких. Бюллетень экспериментальной биологии и медицины. 2007; 144(6): 768-771. doi: http: //dx. doi. org/10. 1007/s10517-007-0427-x.
  38. Raja S.G, Raja S.M. Treating pulmonary arterial hypertension: current treatments and future prospects. Therapeutic Advances in Chronic Disease. SAGE Publications. 2011; 2(6): 359-370. doi: http: //dx. doi. org/10. 1177/2040622311420773
  39. Mecca A.P, Regenhardt R.W, O’Connor T.E, Joseph J.P, Raizada M.K, Katovich M.J et al. Cerebroprotection by angiotensin-(1-7) in endothelin-1-induced ischaemic stroke. Experimental Physiology. Wiley-Blackwell. 2011; 96(10): 1084-1096. doi: http: //dx. doi. org/10. 1113/expphysiol. 2011. 058578.
  40. Novo G, Sansone A, Rizzo M, Guarneri F.P, Pernice C, Novo S. High plasma levels of endothelin-1 enhance the predictive value of preclinical atherosclerosis for future cerebrovascular and cardiovascular events. Journal of Cardiovascular Medicine. Ovid Technologies (Wolters Kluwer Health). 2014; 15(9): 696-701. doi: http: //dx. doi. org/10. 2459/jcm. 0000000000000121.
  41. Nagai M, Terao S, Vital S.A, Rodrigues S.F, Yilmaz G, Granger D. Role of blood cell - associated angiotensin II type 1 receptors in the cerebral microvascular response to ischemic stroke during angiotensin - induced hypertension. Experimental & Translational Stroke Medicine. Springer Nature. 2011; 3(1): 15-24. doi: http: //dx. doi. org/10. 1186/2040-7378-3-15.
  42. Shibuya M. VEGF-VEGFR Signals in Health and Disease. Biomolecules & Therapeutics. The Korean Society of Applied Pharmacology. 2014; 22(1): 1-9. doi: http: //dx. doi. org/10. 4062/biomolther. 2013. 113.
  43. Mat Z, Grensemann B, Yakin Y, Knobloch J, Koch A. Effect of lipoteichoic acid on IL-2 and IL-5 release from T lymphocytes in asthma and COPD. International Immunopharmacology Elsevier BV. 2012; 13(3): 284-291. doi: http: //dx. doi. org/10. 1016/j. intimp. 2012. 04. 005.
  44. Yang J, Shi Q-D, Song T-B, Feng G-F, Zang W-J, Zong C-H et al. Vasoactive intestinal peptide increases VEGF expression to promote proliferation of brain vascular endothelial cells via the cAMP/PKA pathway after ischemic insult in vitro. Peptides. Elsevier BV. 2013; 42: 105-111. doi: http: //dx. doi. org/10. 1016/j. peptides. 2013. 01. 007.
  45. Loza M.J, Watt R, Baribaud F, Barnathan E.S, Rennard S.I. Systemic inflammatory profile and response to anti - tumor necrosis factor therapy in chronic obstructive pulmonary disease. Respiratory Research Springer Nature. 2012; 13(1): 12-24. doi: http: //dx. doi. org/10. 1186/1465-9921-13-12.
  46. Stoll P, Wuertemberger U, Bratke K, Zingler C, Virchow C.J, Lommatzsch M. Stage - dependent association of BDNF and TGF-beta1 with lung function in stable COPD. Respiratory Research. Springer Nature. 2012; 13(1): 116-126. doi: http: //dx. doi. org/10. 1186/1465-9921-13-116.
  47. Aravamudan B, Thompson M, Pabelick C, Prakash Y.S. Brain - derived neurotrophic factor induces proliferation of human airway smooth muscle cells. Journal of Cellular and Molecular Medicine Wiley-Blackwell. 2012; 16(4): 812-823. doi: http: //dx. doi. org/10. 1111/j. 1582-4934. 2011. 01356. x.
  48. Araya J, Nishimura S.L. Fibrogenic Reactions in Lung Disease. Annual Review of Pathology: Mechanisms of Disease. Annual Reviews. 2010; 5(1): 77-98. doi: http: //dx. doi. org/10. 1146/annurev. pathol. 4. 110807. 092217.
  49. Chen A.I et al. The neuroprotective roles of BDNF in hypoxic ischemic brain injury (Review). Biomedical reports. 2013; 1(2): 167-176. doi: http: //dx. doi. org/10. 3892/br. 2012. 48.
  50. Jiang Y, Wei N, Lu T, Zhu J, Xu G, Liu X. Intranasal brain - derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience Elsevier BV. 2011; 172: 398-405. doi: http: //dx. doi. org/10. 1016/j. neuroscience. 2010. 10. 054.
  51. Острова И.В., Аврущенко A.Ш. Экспрессия мозгового нейротрофического фактора (BDNF) повышает устойчивость нейронов к гибели в постреанимационном периоде. Общая реаниматология. 2015; 11(3): 45-53. doi: http: //dx. doi. org/10. 15360/1813-9779-2015-3-45-53.
  52. Doney B, Hnizdo E, Syamlal G, Kullman G, Burchfiel C, Martin C.J et al. Prevalence of Chronic Obstructive Pulmonary Disease Among US Working Adults Aged 40 to 70 Years. Journal of Occupational and Environmental Medicine. Ovid Technologies (Wolters Kluwer Health). 2014; 56(10): 1088-1093. doi: http: //dx. doi. org/10. 1097/jom. 0000000000000232.
  53. Dodd J.W, Chung A.W, van den Broek M.D, Barrick T.R, Charlton R.A, Jones P.W. Brain Structure and Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine American Thoracic Society. 2012; 186(3): 240-245. doi: http: //dx. doi. org/10. 1164/rccm. 201202-0355oc.
  54. Gons R.A.R, van Norden A.G.W, de Laat K.F, van Oudheusden L.J.B, van Uden I.W.M, Zwiers M.P et al. Cigarette smoking is associated with reduced microstructural integrity of cerebral white matter. Brain Oxford University Press (OUP). 2011; 134(7): 2116-24. doi: http: //dx. doi. org/10. 1093/brain/awr145.
  55. Borson S. Modeling the impact of COPD on the brain. International Journal of Chronic Obstructive Pulmonary Disease Dove Medical Press Ltd. 2008; 3(3): 429-434. doi: http: //dx. doi. org/10. 2147/copd. s2066.
  56. Wersching H, Duning T, Lohmann H, Mohammadi S, Stehling C, Fobker M et al. Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology Ovid Technologies (Wolters Kluwer Health). 2010; 74(13): 1022-1029. doi: http: //dx. doi. org/10. 1212/wnl. 0b013e3181d7b45b.
  57. Zhang H, Wang X, Lin J, Sun Y, Huang Y, Yang T et al. Reduced Regional Gray Matter Volume in Patients with Chronic Obstructive Pulmonary Disease: A Voxel-Based Morphometry Study. American Journal of Neuroradiology American Society of Neuroradiology (ASNR). 2012; 34(2): 334-339. doi: http: //dx. doi. org/10. 3174/ajnr. a3235.
  58. Nagai M, Hoshide S, Kario K. The insular cortex and cardiovascular system: a new insight into the brain - heart axis. Journal of the American Society of Hypertension Elsevier BV. 2010; 4(4): 174-182. doi: http: //dx. doi. org/10. 1016/j. jash. 2010. 05. 001.
  59. Lahousse L, Vernooij M.W, Darweesh S.K.L, Akoudad S, Loth D.W, Joos G.F et al. Chronic Obstructive Pulmonary Disease and Cerebral Microbleeds. The Rotterdam Study. American Journal of Respiratory and Critical Care Medicine American Thoracic Society. 2013; 188(7): 783-788. doi: http: //dx. doi. org/10. 1164/rccm. 201303-0455oc.
  60. Greenberg S.M, Vernooij M.W, Cordonnier C, Viswanathan A, Al-Shahi Salman R, Warach S et al. Cerebral microbleeds: a guide to detection and interpretation. The Lancet Neurology Elsevier BV. 2009; 8(2): 165-174. doi: http: //dx. doi. org/10. 1016/s1474-4422(09)70013-4.
  61. Tea Vos. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. The Lancet. 2015. 2015; 386: 743-800. doi: http: //dx. doi. org/10. 1038/sj. bdj. 2015. 751.
  62. Петрик Е.А. Особенности полиморбидности у соматических больных: Автореф. дис.. канд. мед. наук. Москва; 2011. Доступно по: http: //www. cito03. ru/avtoreferat/ petrik. pdf.
  63. Верткин А.Л. Коморбидный пациент. Руководство для практических врачей. М.: Издательство «Эксмо»; 2016.
  64. Lahousse L, van den Bouwhuijsen Q.J.A, Loth D.W, Joos G.F, Hofman A, Witteman J.C.M et al. Chronic Obstructive Pulmonary Disease and Lipid Core Carotid Artery Plaques in the Elderly. American Journal of Respiratory and Critical Care Medicine American Thoracic Society. 2013; 187(1): 58-64. doi: http: //dx. doi. org/10. 1164/rccm. 201206-1046oc.
  65. Chindhi S, Thakur S, Sarkar M, Negi P. Subclinical atherosclerotic vascular disease in chronic obstructive pulmonary disease: Prospective hospital - based case control study. LungIndia. Medknow. 2015; 32(2): 137-141. doi: http: //dx. doi. org/10. 4103/0970-2113. 152624.
  66. Сайфутдинова 3. Р. Клинико - нейрофизиологическое состояние нейромоторной системы у больных хронической обструктивной болезнью легких: Автореф. дис.. канд. мед. наук. Казань; 2007. Доступно по: http: //search. rsl. ru/ru/record/01003057650.
  67. Колчева Ю. А. Энцефалопатия при хроническойобструктивной болезни легких: Автореф. дис.. канд. мед. наук. Санкт-Петербург; 2012. Доступно по: http: //search. rsl. ru/ru/record/01005049058.
  68. Ogoh S, Tsukamoto H, Hirasawa A, Hasegawa H, Hirose N, Hashimoto T. The effect of changes in cerebral blood flow on cognitive function during exercise. Physiological Reports. Wiley-Blackwell. 2014; 2(9): e12163-e12163. doi: http: //dx. doi. org/10. 14814/phy2. 12163.
  69. Dag E, Bulcun E, Turkel Y, Ekici A, Ekici M. Factors Influencing Cognitive Function in Subjects With COPD. Respiratory Care. Daedalus Enterprises. 2016; 61(8): 1044-1050. doi: http: //dx. doi. org/10. 4187/respcare. 04403.
  70. Roncero C, Campuzano A, Quintano J, Molina J, Pérez J, Miravitlles M. Cognitive status among patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease Dove Medical Press Ltd. 2016; 11: 543-551. doi: http: //dx. doi. org/10. 2147/copd. s100850.
  71. Thakur N, Blanc P.D, Julian L.J et al. COPD and cognitive impairment: the role of hypoxemia and oxygen therapy. International journal of chronic obstructive pulmonary disease Dove Medical Press Ltd. 2010; 7(5): 263-269. doi: http: //dx. doi. org/10. 2147/copd. s10684.
  72. Dodd J.W, Getov S.V, Jones P.W. Cognitive function in COPD. European Respiratory Journal. European Respiratory Society (ERS). 2010; 35(4): 913-922. doi: http: //dx. doi. org/10. 1183/09031936. 00125109. doi: http: //dx. doi. org/10. 1136/jnnp-2012-303645.
  73. Laurin C, Moullec G, Bacon S.L, Lavoie K.L. Impact of Anxiety and Depression on Chronic Obstructive Pulmonary Disease Exacerbation Risk. American Journal of Respiratory and Critical Care Medicine American Thoracic Society. 2012; 185(9): 918-23. doi: http: //dx. doi. org/10. 1164/rccm. 201105-0939pp.
  74. Coventry P, Panagioti M, Scott C, Blakemore A. Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease Dove Medical Press Ltd. 2014; 9: 1289-1306. doi: http: //dx. doi. org/10. 2147/copd. s72073.
  75. Maurer J.R. Prevention of panic attacks and panic disorder in COPD. Yearbook of Pulmonary Disease Elsevier BV. 2011; 2011: 43-44. doi: http: //dx. doi. org/10. 1016/j. ypdi. 2010. 11. 033.
  76. Katz P.P, Julian L.J, Omachi T.A, Gregorich S.E, Eisner M.D, Yelin E.H et al. The Impact of Disability on Depression Among Individuals With COPD. Chest Elsevier BV. 2010; 137(4): 838-845. doi: http: //dx. doi. org/10. 1378/chest. 09-1939

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies